Ads
related to: eosinophilic asthma treatment nucala 2 mg tab ivax
Search results
Results From The WOW.Com Content Network
Mepolizumab. Mepolizumab, sold under the brand name Nucala by GlaxoSmithKline, is a humanized monoclonal antibody used for the treatment of severe eosinophilic asthma, eosinophilic granulomatosis with polyangiitis, and hypereosinophilic syndrome (HES). [ 5 ] It recognizes and blocks interleukin-5 (IL-5), a signalling protein of the immune system.
September 6, 2024 at 2:17 AM. (Reuters) -British drugmaker GSK said on Friday that its asthma drug, Nucala, met the main goal of a late-stage study in treating patients with chronic obstructive ...
Benralizumab, sold under the brand name Fasenra, is a monoclonal antibody directed against the alpha chain of the interleukin-5 receptor (CD125). It was developed by MedImmune for the treatment of asthma. [3][4] Two phase III clinical trials of benralizumab reported meeting their primary endpoints in 2016. [5][6] It was approved by the US Food ...
Anti-asthmatic agents. Anti-asthmatic agents refer to drugs that can aid in airway smooth muscle dilation to allow normal breathing during an asthma attack or reduce inflammation on the airway to decrease airway resistance for asthmatic patients, or both. The goal of asthmatic agents is to reduce asthma exacerbation frequencies and related ...
For premium support please call: 800-290-4726 more ways to reach us
EXHALE-2: [5] a global Phase III clinical trial to evaluate the efficacy and safety of dexpramipexole as an add-on oral therapy in participants with inadequately controlled eosinophilic asthma, is currently recruiting people ≥12 years old with a documented physician diagnosis of asthma who require medium to high dose inhaled corticosteroids ...
Ads
related to: eosinophilic asthma treatment nucala 2 mg tab ivax